Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding

被引：0
作者：
Thomas Gremmel
Alexander Niessner
Hans Domanovits
Martin Frossard
Gürkan Sengölge
Barbara Steinlechner
Thomas Sycha
Michael Wolzt
Ingrid Pabinger
机构：
[1] Medical University of Vienna,Department of Internal Medicine II
[2] Landesklinikum Wiener Neustadt,Department of Internal Medicine, Cardiology and Nephrology
[3] Medical University of Vienna,Department of Emergency Medicine
[4] Medical University of Vienna,Department of Trauma Surgery
[5] Medical University of Vienna,Department of Internal Medicine III
[6] Medical University of Vienna,Department of Anesthesia, Intensive Care Medicine and Pain Medicine
[7] Medical University of Vienna,Department of Neurology
[8] Medical University of Vienna,Department of Clinical Pharmacology
[9] Medical University of Vienna,Department of Internal Medicine I
来源：
Wiener klinische Wochenschrift | 2018年 / 130卷
关键词：
NOACs; DOACs; Dabigatran; Factor Xa inhibitors; Consensus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The non-vitamin K antagonist oral anticoagulants (NOACs) have considerably changed clinical practice and are increasingly being used as an alternative to vitamin K antagonists (VKAs) for 3 main reasons: 1) an improved benefit-risk ratio (in particular lower rates of intracranial bleeding), 2) a more predictable effect without the need for routine monitoring, and 3) fewer food and drug interactions compared with VKAs. Currently, there are four NOACs available: the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the thrombin inhibitor dabigatran. This consensus paper reviews the properties and usage of NOACs in a number of high-risk patient populations, such as patients with chronic kidney disease, patients ≥80 years of age and others and provides guidance for the use of NOACs in patients at risk of bleeding.
引用
收藏
页码：722 / 734
页数：12
相关论文
共 288 条
[1]  
Steffel J(2018)The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation Eur Heart J 39 1330-1393
[2]  
Verhamme P(2014)Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants Wien Klin Wochenschr 126 792-808
[3]  
Potpara TS(2016)Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban J Clin Pharmacol 56 637-645
[4]  
Albaladejo P(2016)Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis Am J Nephrol 43 229-236
[5]  
Antz M(2015)Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis Thromb Haemost 113 719-729
[6]  
Desteghe L(2013)Dabigatran versus Warfarin in Patients with Mechanical Heart Valves N Engl J Med 396 1206-1214
[7]  
Pabinger I(2016)2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-2962
[8]  
Lang W(2013)Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Kidney Int Suppl 3 1-50
[9]  
Roithinger FX(2015)Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation Europace 17 1467-1507
[10]  
Weidinger F(2009)Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Circulation 119 1363-1369
12345678910